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BINDING OF THE CHEMICAL CARCINOGEN, p-DIMETHYLAMINOAZOBENZENE, 
BY HUMAN PLASMA LOW DENSITY LIPOPROTEINS 
1. Introduction 
Human plasma lipoproteins are lipid-protein com- 
plexes that transport water-insoluble lipids in the 
circulation and regulate lipid synthesis and catabolism 
[l-3], For many years, the plasma lipoproteins have 
attracted the attention of investigators interested in 
lipid transport [4,5] and cardiovascular disease, How- 
ever, in addition to their involvement in lipid transport 
and metabolism, other roles for the plasma lipo- 
proteins have been~recognized r cently9 inclu~ng 
inhibition of lymphocyte proliferation [6] and main- 
tenance of immunologic homeostasis [7]. Plasma lipo- 
proteins transport not only lipids but other lipophilic 
materials uch as the drug reserpine [S], &carotene 
and lycopene. a-Tocopherol and dolichol [9] are 
specifically associated with human plasma low 
density lipoproteins (LDL) and high density lipo- 
proteins (HDL), respectively. Benditt [IO] has sug- 
gested that two potential mutagens, benzo~a]pyrene 
(BP) and me~ylchol~threne~ are also carried by the 
lipoproteins. It is believed that the blood is the main 
transport mechanism in cases of chemical carcinogens 
or drug action where systemic effects are observed 
Dr.1. 
p-Dimethylaminoazobenzene (DAB), also known 
as butter yellow, is included in category 1 on the 
tentative carcinogen list issued by the Occupational 
Safety and Health Administration, USA [ 121. DAB- 
induced carcinogenesis in animals has been studied 
extensively [53,14]. We report here that this water- 
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insoluble carcinogen associates primarily with the 
human plasma low density lipoproteins (LDL). 
2. Materials and methods 
The present study was performed with unpooled 
plasma obtained from normal healthy male and 
female subjects. Lipoproteins were isolated by the 
method of Rude1 et al. [ 15]- The solvent density of 
human plasma was increased to 1.225 gfml by the 
addition of solid K3r and total lipoproteins were 
isolated by uitracentrifugation with a Becktnan 
60 Ti rotor at 45 000 rev./min and 10°C for 48 h. After 
dialysis against 0.01 M Tris, 0.1 M NaCl, 0.01% 
EDTA, 0.02% sodium azide, pH 7.4, the lipoproteins 
(1 ml) were chromatographed ona BioGel A-l 5 m 
(200-400 mesh) agarose column (1.6 X 90 cm) 
which was eluted at 8 ml/h. p-Dimethylaminoazo- 
benzene [phenyl-14C] (f4C-DAB) was obtained from 
New England Nuclear with a specific activity of 
4.5 mCi/mM and purity >99%, abut (fraction V) 
was from Miles Laboratories, Elkhart, Indiana, USA. 
Incorporation of 34C-DAB into whole blood, human 
plasma lipoproteins, and plasma lbumin was per- 
formed as follows. About 0.5 clCi of 14C-DAB was 
dissolved in 1 ml of benzene and evaporated to dry- 
ness in a test tube with ultrapure nitrogen. 1 ml of 
whole blood, plasma lipoprotein solution, or albumin 
solution was added and then incubated with stirring 
at 3’7°C for 6 h. In the DAB binding capacity experi- 
ments which did not involve blood cells, undissolved 
DAB was removed by centrifugation at 4000 X g for 
10 min. The transparent hpoprote~ mixture solution 
was resolved into its component lipoprotein classes 
by gel filtration as described above. 
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3. Results and discus&n 
~c~bation of s4C-DAB with 1 mX,of whole blood 
was attended by the distribution of 15% of the radio- 
activity into cellular components, the remainder 
being bound to the lipoprote~s and lipid~f~~~ plasma 
proteins, In order to determine the distribution of the 
carcinogen among the lipoproteins, the three principal 
cktsses (VLDL, LDL, HDL) were separated by agarose 
FRACTION NUMBER 
Fig.1, (A) Elution profile of plasma ~poprote~s isolated by 
ultracentrifugation at d = 1.225 g/ml and separated on a 
BioGet A-15m agarose column (1.5 X 95 cm) at 24’C. A 
1.0 ml sample volume (26 tng of lipoprotein} was eluted with 
0.01. M Ii&--HCi buffer, pH 7.4, containing 0.10 M Nail, 
0.01% EDTA and 0.02% NaN,. (B) D~tribution of ‘T-DAB 
(cpm~~action} among a mixture of VLDL, LDL, and HDL- 
The ~ipoprote~ (26 mg total in 1 ml) were incubated with 
0.5 &Zf of “C-DAB and then separated by gel fdtration as 
described In the text and fig.lA. 
FRACTION NUMBER 
Fig.2. (A) Elution profile indicating the distribution of 14C- 
DAB (cpm/fraction) among the lipoproteins in the presence 
of an exogenously added, physiological ratio of human serum 
albumin. ~omato~apbic conditions were identical to those 
described in fig+ 1A. (B) Elution profile ~us~tin~ the distri- 
bution of ‘Y!-DAB between LDL (13.2 mg) and HSA 
(150 mg) wbicn were present in 1 mI buffer and were at their 
normal plasma ratio. The LDL is present at a couce~~atio~ 
comparable to that of the experiment shown in flg.iB. 
gel filtration chromatography. Figure 1A illustrates 
the quality of the separation of these three particle 
populations. A&bough the extinction coefficient at 
280 nm for each lipoprotein type is not the same, 
thereby preventing a direct comparison of the relative 
amounts of each, Aam measurements dopermit an 
estimate of the amount of material present, Incuba- 
tion of a I ml aliquot of the same pfasma s used in 
f@.lA with r4C-DAR resulted in the ~str~butio~ of 
radioactivity among the lipoproteins as illustrated in 
237 
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fig.lB. About 77% of the incorporated r4C-DAB was 
associated with LDL, while 10% and 13% were 
associated with VLDL and HDL, respectively. When 
14C-DAB was incubated with the total plasma lipo- 
protein mixture and a physiologically equivalent 
amount of plasma lbumin (150 mg), the distribution 
of 14C-DAB among the lipoproteins was only modestly 
altered (65% in LDL, 9% in VLDL, and 26% in HDLf 
albumin) (fig.2A). The 12% decrease in DAB binding 
to LDL observed when albumin was in the lipoprote~ 
mixture prompted us to more closely examine the 
effect of albumin on DAB binding to LDL. Incuba- 
tion of i4C-DAB (at a subsaturating level) with LDL 
and albumin present at a normal physiological ratio 
resulted in the distribution of 88% of the radioactivity 
into the LDL and 12% into the albumin fraction 
(fig2B). 
To insure that the binding of DAB to LDL was 
complete under the conditions employed, the time- 
dependence of this binding was examined. A maximum 
of 0.25 mg DAB was bound to 2.6 mg LDL at 37°C. 
Greater than 50% maximal binding was observed 
within the first 10 min, while about 95% binding 
occurred within the first 4 h (fig.3). 
From the above studies it is clear that in mixtures 
of lipoproteins either containing or excluding albumin, 
DAB at subsaturating levels binds predominantly to 
LDL. In order to evaluate the possible influence on 
DAB binding to a lipoprotein by one or more other 
lipoprotein types, the DAB binding capacity of each 
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Fig.3. The rate of DAB saturation binding to LDL. The 
experimental details are the same as in fig.4, except that a 
constant saturating level of DAB (2.5 mg) was used. 
0.5 1.0 t.5 2.0 2.5 
DAB present fmg) 
FigA. DAB binding capacity of VLDL, LDL, HDL and HSA. 
Each component, at its normal plasma concentration, was 
incubated with increasing amounts of Y-DAB at 37°C for 
12 h. Undissolved DAB was removed by centrifugation 
(4000 rev./min, 10 min). An aliquot of the supematant wasused 
for quantitation. The figure indicates the total DAB (mg) 
found in the supernatant at each concentration of DAB. No 
additional DAB was found in the supernatant with extended 
time (up to 48 h). 
mined separately (tig.4). These experiments were con- 
ducted at phy~olo~cal concentrations. LDL, normally 
present at about 2.6 mg/ml, bound 0.24 mg DAB 
which was about three times greater than that bound 
by VLDL and four times greater than that bound by 
HDL at their respective plasma concentrations. 
In normal male (30-39 years) plasma s used in 
this study, the mean VLDL, LDL, and HDL concen- 
trations are 90,262, and 283 mg%, respectively [16]. 
Since these particles contain about 90,80, and 50% 
lipid by weight, the relative percentage of lipid trans- 
ported by each type is approx~ately 19,48, and 
33%, respectively. Hence, the dist~bution of a major 
portion of DA3 into the LDL is ~derstandable, at
least in part, in terms of the fraction of total lipids 
transported by these lipoproteins. 
The above argument predicts that altering the 
relative abundance of lipoprotein classes will affect 
the distribution of DAB among them if it undergoes 
sufficiently rapid chemical exchange. Cholesterol and 
phospholipid are known to exchange or transfer 
among lipoproteins and between the various blood 
components [ 1,201. Accordingly, the transfer of DAB 
under non-physiolo~c~ lipoprote~ ratio conditions 
was tested. At equal protein concentrations (1.O mg/ml) 
for each lipoprotein class, 53% of the “C-DAB 
originally associated with LDL transferred to VLDL, 
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10% to HDL, while <5% transferred to albumin 
which was present at 10 times the apolipoprotein 
concentration. The high efficiency of 14C-DAB 
transfer from LDL to VLDL is similar to that found 
for benzo [a] pyrene (BP) by Shu and Nichols [ 17]+. 
Like DAB, BP was found to bind predominantly to 
LDL. When BP was incubated with the plasma from 
a hypertriglyceridemic patient, the VLDL became its 
primary carrier. 
The observation that 17-29% more DAB distributes 
into LDL than is predicted suggests hat the lipo- 
protein may possess unique structural features 
[3,17-191 which favor DAB binding. 
Although our study does not establish the actual 
binding site(s) for the DAB, the extremely apolar 
lipid core of VLDL and LDL [3] would be a logical 
candidate for this function. Indeed, the lipophilicity 
(decimal logarithm of the partition coefficient) of 
DAB was determined for the octanol-water system 
and found to be 4.26 + 0.11. This relatively high lipo- 
philicity, compared to a number of sterols (e.g. 
progesterone and testosterone) [21], strongly suggests 
that it is indeed the hydrophobic ore of these lipo- 
proteins where DAB is bound. 
The binding of chemical carcinogens or drugs at 
non-active sites such as plasma lbumin and lipo- 
proteins has important biological implications ince 
these entities may influence access to sites of bio- 
transformation, action, and excretion. Although 
plasma lbumin, the most abundant protein in the 
blood, is the major drug-binding protein 1221, Gillette 
[23] and Chen et al. [8] have pointed out that drugs 
may bind to other plasma proteins. In the case of the 
two water-~soluble chemical carcinogens, DAB and 
BP, both are found associated mainly with plasma 
LDL, not albumin. If LDL is the major transport 
vehicle for water-insoluble carcinogens in vivo, the 
ramifications may be profound. Specific receptor 
sites for LDL exist in a variety of normal cells such as 
human fibroblasts, lymphocytes, and arterial smooth 
+ While this manuscript was in preparation, the report of Shu 
and Nichols [ 171 was published. Their results for the bind- 
ing of benzo[a]pyrene to human plasma lipoproteins are 
very similar to those described here for DAB. The majority 
of BP was found associated with the VLDL and LDL, and 
the distribution of this carcinogen was found to depend on 
the relative abundance of the different lipoprotein classes. 
muscle cells 1241. The interaction of LDL with this 
specific receptor initiates a series of complex processes 
involving endocytosis and lysosomal degradation of
the internalized LDL, with concomitant activation of 1 
acyl-coenzyme A : cholesterol acyltransferase (ACAT) 
and suppression of HMG-CoA reductase within cul- 
tured cells (241. The transfer of chemical carcinogens 
from LDL to cells by either this process or by some 
other transfer mechanism ight cause neoplastic 
tr~sformations if the accessible cells possess the 
enzyme systems responsible for c~cinoge~c metabolic 
activation [131. This process might also serve as an 
initiation factor in the transformation of arterial 
smooth muscle cells followed by a progressive l sion 
development with the formation of atheromata [25]. 
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